홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Triethylamine → N-(4-(1-(4-methoxybenzyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide

HRID 2241414
인쇄

반응식

HRID 2241414 반응식
CCN=C=NCCCN(C)C.[F:12][C:13]1[CH:18]=[CH:17][C:16]([N:19]2[C:24](=[O:25])[C:23]([C:26]([OH:28])=O)=[CH:22][CH:21]=[N:20]2)=[CH:15][CH:14]=1.[CH3:29][O:30][C:31]1[CH:65]=[CH:64][C:34]([CH2:35][N:36]2[C:40]3=[N:41][CH:42]=[CH:43][C:44]([O:45][C:46]4[CH:51]=[CH:50][C:49]([NH2:52])=[CH:48][C:47]=4[F:53])=[C:39]3[C:38]([N:54]3[CH2:59][CH2:58][N:57]([CH2:60][CH2:61][O:62][CH3:63])[CH2:56][CH2:55]3)=[N:37]2)=[CH:33][CH:32]=1.C(N(CC)CC)C>CN(C=O)C.CCOC(C)=O>[CH3:29][O:30][C:31]1[CH:32]=[CH:33][C:34]([CH2:35][N:36]2[C:40]3=[N:41][CH:42]=[CH:43][C:44]([O:45][C:46]4[CH:51]=[CH:50][C:49]([NH:52][C:26]([C:23]5[C:24](=[O:25])[N:19]([C:16]6[CH:15]=[CH:14][C:13]([F:12])=[CH:18][CH:17]=6)[N:20]=[CH:21][CH:22]=5)=[O:28])=[CH:48][C:47]=4[F:53])=[C:39]3[C:38]([N:54]3[CH2:59][CH2:58][N:57]([CH2:60][CH2:61][O:62][CH3:63])[CH2:56][CH2:55]3)=[N:37]2)=[CH:64][CH:65]=1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

7

반응물 4

HCID 8471TriethylamineHCID 159081-Ethyl-3-(3'-dimethylaminopropyl)carbodiimideHCID 667671712-(4-Fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxylic acidHCID 685138364-(1-(4-methoxybenzyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorobenzenamine

생성물 1

HCID 68513921
N-(4-(1-(4-methoxybenzyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide
수율 10%

시약·촉매·용매 2

HCID 6228Dimethylformamide용매HCID 8857Ethyl Acetate용매

실험 절차

EDCI (27 mg, 0.14 mmol) was added to a stirred mixture of 2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxylic acid (11 mg, 0.047 mmol, prepared according to the procedure described for Example 19, Step C) and HOBt-hydrate (22 mg, 0.14 mmol) in DMF (0.3 mL) at ambient temperature, and the reaction mixture was stirred for 15 minutes at ambient temperature. 4-(1-(4-Methoxybenzyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorobenzenamine (12 mg, 0.024 mmol) and triethylamine (0.020 ml, 0.14 mmol) were then added, and the resulting mixture was stirred for 18 hours at ambient temperature. The reaction mixture was diluted with EtOAc and washed with water. The aqueous phase was re-extracted with EtOAc. The combined organic phases were washed with water, dried (Na2SO4), filtered, and concentrated in vacuo. The crude material was purified by preparative TLC (0.5 mm) and eluted with 15% MeOH/DCM (Rf=0.74). The product was obtained as a waxy solid (2 mg, 10%).

후처리

  1. customprepared
  2. customat ambient temperature
  3. stirringthe resulting mixture was stirred for 18 hours at ambient temperature
  4. washwashed with water
  5. extractionThe aqueous phase was re-extracted with EtOAc
  6. washThe combined organic phases were washed with water
  7. dry with materialdried (Na2SO4)
  8. filtrationfiltered
  9. concentrationconcentrated in vacuo
  10. customThe crude material was purified by preparative TLC (0.5 mm)
  11. washeluted with 15% MeOH/DCM (Rf=0.74)

출처 및 근거

ORD 기록
ord-d3bbcb1bc4b34aa192ee2fb316c6ad56
출처 데이터셋
uspto-grants-2010_05
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US07723330B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트